China Resources Pharmaceutical Group Dividends and Buybacks
Dividend criteria checks 1/6
China Resources Pharmaceutical Group is a dividend paying company with a current yield of 2.27% that is well covered by earnings. Next payment date is on 14th July, 2025 with an ex-dividend date of 28th May, 2025.
Key information
2.3%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 4.2% |
| Dividend Growth | 9.9% |
| Next dividend pay date | 14 Jul 25 |
| Ex dividend date | 28 May 25 |
| Dividend per share | HK$0.111 |
| Payout ratio | 25% |
Recent dividend and buyback updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28Recent updates
Earnings Miss: China Resources Pharmaceutical Group Limited Missed EPS By 21% And Analysts Are Revising Their Forecasts
Mar 28Calculating The Intrinsic Value Of China Resources Pharmaceutical Group Limited (HKG:3320)
Mar 27China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Feb 11Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Dec 19China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 3320 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 3320's dividend payments have increased, but the company has only paid a dividend for 8 years.
Dividend Yield vs Market
| China Resources Pharmaceutical Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (3320) | 2.3% |
| Market Bottom 25% (HK) | 3.0% |
| Market Top 25% (HK) | 8.0% |
| Industry Average (Pharmaceuticals) | 3.0% |
| Analyst forecast (3320) (up to 3 years) | 4.2% |
Notable Dividend: 3320's dividend (2.27%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (3.02%).
High Dividend: 3320's dividend (2.27%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.02%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (25.5%), 3320's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Insufficient data to calculate 3320's cash payout ratio to determine if its dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/18 11:56 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Pharmaceutical Group Limited is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Zhishun Siu | CCB International Securities Limited |
| Yanyin Zhu | China International Capital Corporation Limited |